{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:45Z","timestamp":1792239045107,"version":"4.4.0"},"reference-count":75,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Accumulating real-world (RW) evidence of axicabtagene ciloleucel (axi-cel) has demonstrated comparable performance to that of pivotal trials. However, \u223c57% of patients eventually relapse, with most requiring additional therapies. Being able to identify patients with risk of early relapse enables clinicians to consider additional interventions to extend survival outcomes. This study aimed to first comprehensively evaluate the RW performance of axi-cel in the multicenter University of California Health Systems using automated computational approaches. Second, we developed a decision tree machine learning (ML) model to identify patients with risks of early relapse within 6 months. A total of 416 adult patients with diffuse large B-cell lymphoma (DLBCL) receiving axi-cel between 2017 and 2024 were included in the study. The median progression-free survival (PFS) and overall survival (OS) were 10.1 and 54.4 months; the 18-month PFS and OS rates were 41.6% and 65.5%, respectively. Severe CRS and ICANS were observed in 18.8% and 32.5% of patients. The ML model, relying on age and 6 routinely measured laboratory tests (lactate dehydrogenase, C-reactive protein, ferritin, hematocrit, platelet count, and prothrombin time), achieved a high area under the receiver operating characteristic curve score of 0.82. The decision curve analysis indicated positive net benefit of the model across a broad range (0-0.7) of decision thresholds, suggesting clinical utility in diverse scenarios. This study further confirmed the RW performance of axi-cel in diverse populations. Our ML model represented a novel approach to identify patients that may benefit from additional interventions to extend survival outcomes. Following prospective confirmation study, our model and decision tree approach may support clinical decision making in patients with high-risk DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016375","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:00:08Z","timestamp":1756926008000},"page":"5837-5852","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["An AI model classifies risks of early relapse post\u2013CAR T-cell therapy in a multicenter real-world population with DLBCL"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3207-1490","authenticated-orcid":false,"given":"Michelle","family":"Wang","sequence":"first","affiliation":[{"name":"1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA"},{"name":"2Department of Pediatrics, University of California San Francisco, San Francisco, CA"},{"name":"3Department of Bioengineering and Therapeutic Sciences, Graduate Program in Pharmaceutical Sciences and Pharmacogenomics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"},{"name":"5Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debajyoti","family":"Datta","sequence":"additional","affiliation":[{"name":"1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA"},{"name":"2Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan","family":"Patel","sequence":"additional","affiliation":[{"name":"1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA"},{"name":"2Department of Pediatrics, University of California San Francisco, San Francisco, CA"},{"name":"6Center for Data-driven Insights and Innovation, University of California Health, Oakland, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-6268","authenticated-orcid":false,"given":"Barbee","family":"Whitaker","sequence":"additional","affiliation":[{"name":"7Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6848-1224","authenticated-orcid":false,"given":"Artur","family":"Belov","sequence":"additional","affiliation":[{"name":"7Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rubin","sequence":"additional","affiliation":[{"name":"1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA"},{"name":"2Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Vashist","sequence":"additional","affiliation":[{"name":"1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA"},{"name":"2Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-9395","authenticated-orcid":false,"given":"Rosa","family":"Rodriguez-Monguio","sequence":"additional","affiliation":[{"name":"8Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA"},{"name":"9Medication Outcomes Center, University of California San Francisco, San Francisco, CA"},{"name":"10Philip R. Lee Institute for Health Policy Studies, School of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Cinar","sequence":"additional","affiliation":[{"name":"5Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"},{"name":"11Division of Medical Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Anderson","sequence":"additional","affiliation":[{"name":"6Center for Data-driven Insights and Innovation, University of California Health, Oakland, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul J.","family":"Butte","sequence":"additional","affiliation":[{"name":"1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA"},{"name":"2Department of Pediatrics, University of California San Francisco, San Francisco, CA"},{"name":"3Department of Bioengineering and Therapeutic Sciences, Graduate Program in Pharmaceutical Sciences and Pharmacogenomics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2025112508462099200_bib1","unstructured":"Key Statistics for Non-Hodgkin Lymphoma. American Cancer Society. Accessed 30 November 2020. https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/about\/key-statistics.html."},{"issue":"16","key":"2025112508462099200_bib2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2025112508462099200_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"2025112508462099200_bib4","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025112508462099200_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025112508462099200_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112508462099200_bib7","unstructured":"FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma. FDA. Accessed 23 April 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma."},{"issue":"5","key":"2025112508462099200_bib8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.20.01749","article-title":"Chimeric antigen receptor T-cell therapy in the management of relapsed non-Hodgkin l","volume":"39","author":"Komanduri","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025112508462099200_bib9","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2025112508462099200_bib10","first-page":"750","article-title":"Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis","volume":"29","author":"Derigs","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"2025112508462099200_bib11","first-page":"725","article-title":"Long-term survivors and failures of CAR-T therapy for lymphoma: is there a role for allogeneic transplantation after the CAR-T crash?","volume":"29","author":"Spinner","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"24","key":"2025112508462099200_bib12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"2025112508462099200_bib13","unstructured":"YESCARTA\u00ae (axicabtagene ciloleucel). FDA. Accessed 30 November 2020. https:\/\/www.fda.gov\/media\/108377\/download."},{"key":"2025112508462099200_bib14","unstructured":"FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. FDA. Accessed 4 March 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous."},{"issue":"4","key":"2025112508462099200_bib15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"20","key":"2025112508462099200_bib16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025112508462099200_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"2025112508462099200_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang","year":"2021","journal-title":"J Immunother Precis Oncol"},{"issue":"12","key":"2025112508462099200_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clml.2021.07.002","article-title":"Real-world experience of axicabtagene ciloleucel and tisagenlecleucel for relapsed or refractory aggressive B-cell lymphomas: a single-institution experience","volume":"21","author":"Ghafouri","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2025112508462099200_bib20","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025112508462099200_bib21","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/ refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"issue":"19","key":"2025112508462099200_bib22","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.3390\/cancers13194789","article-title":"Real world evidence of CAR T-cell therapies for the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma: a monocentric experience","volume":"13","author":"Casadei","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"2025112508462099200_bib23","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025112508462099200_bib24","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2021-149679","article-title":"Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL): impact of age and specific organ dysfunction","volume":"138","author":"Locke","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025112508462099200_bib25","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025112508462099200_bib26","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/blood-2022-163750","article-title":"Impact of age on outcomes after CD19 directed CAR T cell therapy for large B cell lymphomas: real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)","volume":"140","author":"Mirza","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025112508462099200_bib27","article-title":"Response to bridging therapy (BT) before CAR-T cell infusion predicts outcomes for relapsed\/refractory (R\/R) aggressive B-cell non-Hodgkin lymphoma (NHL)","volume":"136","author":"Khurana","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025112508462099200_bib28","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","article-title":"An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"HemaSphere"},{"issue":"1","key":"2025112508462099200_bib29","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.19152","article-title":"Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function","volume":"204","author":"Mamlouk","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"2025112508462099200_bib30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025112508462099200_bib31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2025112508462099200_bib32","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"22","key":"2025112508462099200_bib33","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025112508462099200_bib34","article-title":"Comorbidities predict inferior survival in patients receiving CAR T-cell therapy for relapsed\/refractory DLBCL: a multicenter retrospective analysis","volume":"134","author":"Kittai","year":"2019","journal-title":"Blood"},{"key":"2025112508462099200_bib35","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"2025112508462099200_bib36","volume-title":"Center for Data-driven Insights and Innovation Annual Report","year":"2020"},{"key":"2025112508462099200_bib37","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Accessed 2 June 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40."},{"issue":"2","key":"2025112508462099200_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2025112508462099200_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"2025112508462099200_bib40","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"2025112508462099200_bib41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","article-title":"Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing","volume":"20","author":"Noaks","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"2025112508462099200_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.21849","article-title":"Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil\/lymphocyte ratio","volume":"85","author":"Porrata","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"2025112508462099200_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.hemonc.2021.09.001","article-title":"Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma","volume":"16","author":"Forero-Forero","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"2025112508462099200_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2025112508462099200_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"355","key":"2025112508462099200_bib46","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"8","key":"2025112508462099200_bib47","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","article-title":"Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse","volume":"5","author":"Faude","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"2025112508462099200_bib48","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025112508462099200_bib49","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1038\/s41598-021-82087-6","article-title":"High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma","volume":"11","author":"Jung","year":"2021","journal-title":"Sci Rep"},{"issue":"1-2","key":"2025112508462099200_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"2025112508462099200_bib51","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(21)00412-5","article-title":"CAR T cells for the long run in aggressive B-cell lymphoma","volume":"22","author":"Jacoby","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6434","key":"2025112508462099200_bib52","doi-asserted-by":"crossref","first-page":"eaau0135","DOI":"10.1126\/science.aau0135","article-title":"T cell stemness and dysfunction in tumors are triggered by a common mechanism","volume":"363","author":"Vodnala","year":"2019","journal-title":"Science"},{"issue":"4","key":"2025112508462099200_bib53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","article-title":"The Lasso method for variable selection in the Cox model","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat Med"},{"key":"2025112508462099200_bib54","unstructured":"CAR T Cell Therapy Multi-Center Real-World Analysis. GitHub. Accessed 10 September 2025. https:\/\/github.com\/m10wang\/CART_analysis."},{"issue":"suppl 1","key":"2025112508462099200_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood-2024-209093","article-title":"Real-world trends of cytokine release syndrome and neurologic events, and pattern of their management among patients receiving axicabtagene ciloleucel for relapsed or refractory (r\/r) large B-cell lymphoma (LBCL) in the US: a CIBMTR report","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"16 suppl","key":"2025112508462099200_bib56","article-title":"Predictors of severe CRS in longitudinal CAR T-cell clinical trial data","volume":"40","author":"Strait","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025112508462099200_bib57","first-page":"581.e1","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2025112508462099200_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2025112508462099200_bib59","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2025112508462099200_bib60","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"13","key":"2025112508462099200_bib61","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2025112508462099200_bib62","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2025112508462099200_bib63","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","article-title":"Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy","volume":"10","author":"Gurney","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"2025112508462099200_bib64","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"27","key":"2025112508462099200_bib65","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112508462099200_bib66","first-page":"100603","article-title":"Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy","volume":"32","author":"Caliman","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"8","key":"2025112508462099200_bib67","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/bloodadvances.2024012563","article-title":"Monocytes in leukapheresis products affect the outcome of CD19\u2013targeted CAR T-cell therapy in patients with lymphoma","volume":"8","author":"Carniti","year":"2024","journal-title":"Blood Adv"},{"issue":"16","key":"2025112508462099200_bib68","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"20","key":"2025112508462099200_bib69","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2025112508462099200_bib70","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"2025112508462099200_bib71","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"2025112508462099200_bib72","doi-asserted-by":"crossref","first-page":"702644","DOI":"10.3389\/fonc.2021.702644","article-title":"New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2025112508462099200_bib73","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.2147\/CMAR.S321202","article-title":"Cytopenias after CD19 chimeric antigen receptor T-cells (CAR-T) therapy for diffuse large B-cell lymphomas or transformed follicular lymphoma: a single institution experience","volume":"13","author":"Schaefer","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"6","key":"2025112508462099200_bib74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112508462099200_bib75","doi-asserted-by":"crossref","first-page":"1110028","DOI":"10.3389\/fimmu.2023.1110028","article-title":"Predictive short\/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed\/refractory B-cell lymphomas","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5837\/2420553\/blooda_adv-2025-016375-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5837\/2420553\/blooda_adv-2025-016375-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:46:38Z","timestamp":1764078398000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5837\/547095\/An-AI-model-classifies-risks-of-early-relapse-post"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":75,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016375","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,14]]}}}